Ann: Neuren and ACADIA announce agreement for North America, page-387

The deal has put NEU in play. We now have a buyer. ACAD will want more. And whoever was stalking ACAD will want it more than ever now. Most SI investors recognise that NEU will be up for sale at a much higher price after this deal. The problem for investors is when will the action starts. VLA took a few years. Or as Hottod posts today deals can roll out relatively quickly. Including more territories.

There is also a very strong possibility that ACAD could apply and get issued with 2 Priority Review Vouchers which could bring in another $80m for NEU.

It’s also a possibility that ACAD might apply for FAST TRACK again. Now Trump has told FDA to approve drugs once they have a proven safety profile. With the support of RETTS and FXS support groups this is also a possibility.

So , it’s my belief there are plenty of possible triggers to move NEU up in price. For all we know BELLS might be writing a new analyst report which has more info provided by Treagus. Broking firms always get the CEO/Chairman to proof read their analysis for accuracy before releasing it. That’s standard practice.

It may be prudent to let th dust settle here before throwing the baby out.